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Background: Interleukin-27 (IL-27) has been recognized as a pleiotropic cytokine with both pro- and anti-inflammatory
properties. Few studies have investigated polymorphisms and serum/plasma levels of IL-27 in diseases including cancers.
This study has analyzed the associations of IL-27 gene polymorphisms, as well as plasma levels of IL-27, with susceptibility
to bladder cancer and clinical outcome.
Methods: Three hundred and thirty-two patients (nonmuscle-invasive bladder cancer (NMIBC)/muscle-invasive bladder
cancer (MIBC): 176/156) included in a 60-month follow-up program and 499 controls were enrolled. Two single nucleotide
polymorphisms (SNPs), rs153109 and rs17855750, were genotyped by polymerase chain reaction (PCR) -restriction
fragment length polymorphism (RFLP) method. Plasma concentration of IL-27 was determined by ELISA in 124 patients
(NMIBC/MIBC: 50/74) and 151 controls.
Results: Significantly increased risk for bladder cancer was associated with AG/GG genotypes of rs153109 (P = 0.029). No
GG genotype of rs17855750 was observed in controls, while 4 patients were found to be GG homozygotes, suggesting
GG genotype may be associated with bladder cancer risk (P = 0.006). For bladder cancer patients, SNP rs17855750 was
also associated with increased risk for MIBC. For MIBC patients, but not NMIBC, TG/GG genotypes of rs17855750 turned
out to be a protective factor for overall survival (P = 0.035). Significantly reduced plasma levels of IL-27 were observed in
both NMIBC and MIBC patients compared with controls (P < 0.0001).
Conclusion: Our data suggest that polymorphisms and reduced plasma levels of IL-27 may predict the susceptibility to
bladder cancer, and rs17855750 may be a useful marker to distinguish patients with high risk of death.
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Bladder cancer is one of the most common cancers
worldwide and the most frequent malignancy of the
urinary tract [1]. In China, bladder cancer is the tenth
most common cancer, accounting for 17,365 deaths in
2005 and mortality has steadily increased between 1991
and 2005 [2]. Transitional cell carcinoma of the urinary* Correspondence: zhanglin@scu.edu.cn
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cers, approximately 80 % of which are nonmuscle-
invasive bladder cancer (NMIBC). The vast majority of
cancer-specific deaths are due to muscle-invasive blad-
der cancer (MIBC), although only about 20 % of bladder
cancer patients are diagnosed with MIBC. Tobacco
smoking and occupational or environmental exposure
to chemical carcinogens are the most and well-
established risk factors for bladder cancer. However,
only a few of the exposed individuals develop bladder
cancer in their lifetime, suggesting that genetic factor
may also play a crucial role in the pathogenesis of blad-
der cancer [3].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of the study population
NMIBC group MIBC group Controls
Sex
Male 137 (77.8) 126 (80.8) 381 (76.4)
Female 39 (22.2) 30 (19.2) 118 (23.6)
Age at first diagnosis
(mean ± SD)
61.96 ± 12.88 65.85 ± 10.98 64.51 ± 5.71
Smoking status
Smokers 90 (51.1) 85 (54.5) 241 (48.3)
Non-smokers 86 (48.9) 71 (45.5) 258 (51.7)
Clinical stage
Ta 10 (5.7) - -
T1 166 (94.3) - -
T2 - 91 (58.3) -
T3a - 36 (23.1) -
T3b - 18 (11.5) -
T4 - 11 (7.1) -
Tumor grade
Low grade 119 (67.6) 25 (16.0) -
High grade 57 (32.4) 131 (84.0) -
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ing proliferative signaling, evading growth suppressors,
resisting cell death, enabling replicative immortality, indu-
cing angiogenesis, activating invasion and metastasis, re-
programming of energy metabolism, and evading immune
destruction [4, 5]. Clinical and epidemiologic studies have
suggested that inflammation can play a direct role in
cancer [6, 7]. Inflammation, which orchestrates the tumor
microenvironment, is involved in tumor initiation, promo-
tion, and progression [8–10]. In bladder carcinogenesis,
findings from numerous studies have suggested that
inflammation is likely to have an important role [11]. C-
reactive protein (CRP), which is an acute-phase reactant
and a useful marker of systemic inflammation, has been
shown to be a biomarker for bladder cancer [12–14].
Interleukin-27 (IL-27) is a heterodimeric cytokine com-
posed of the Epstein-Barr virus-induced gene 3 (EBI3) and
IL-27p28, which engages a receptor composed of gp130
and the IL-27Rα that activates Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) and
mitogen activated protein kinase (MAPK) signaling [15,
16]. IL-27, which is a member of the IL-12 family of cyto-
kines and chiefly produced by antigen-presenting cells
(APC) such as dendritic cell (DCs) and macrophages, was
initially described as a proinflammatory cytokine that pro-
moted T helper (Th)1 responses [17]. Subsequent studies
have confirmed an anti-inflammatory role for IL-27 in
Th1, Th2, and Th17 responses, and it has also been shown
that IL-27 can induce T cells to produce the anti-
inflammatory cytokine IL-10 [18–20]. Of note, recent
studies have revealed that IL-27 exerts potent antitumor
effects against various tumor models via different mecha-
nisms, including CD8+T cells, natural killer (NK) cells,
antibody-dependent cell-mediated cytotoxicity (ADCC),
antiangiogenesis, direct suppression of tumor growth, and
inhibition of cychroxygenase-2 (COX-2) expression, de-
pending on the characteristic of each tumor [21–25].
The associations between polymorphisms of IL-27 gene,
as well as serum/plasma levels of IL-27 and various
human disorders including asthma, inflammatory bowel
diseases, chronic obstructive pulmonary disease (COPD),
colorectal cancer, esophageal cancer, and glioma have
been studied [26–33]. Accordingly, the present study ana-
lyzed the influence of IL-27 polymorphisms and plasma




A hospital-based case–control study was conducted
including 332 unrelated patients with transitional cell
carcinoma of bladder between 2006 and 2010 derived
from the West China Hospital of Sichuan University.
The diagnosis of bladder cancer was confirmed in allcases by histological examination of tissue from resected
specimens. Clinical and follow-up data were abstracted
from patients’ medical records and by telephone calls.
The control group consisted of 499 healthy subjects
from a routine health survey in the same hospital.
Table 1 summarized the baseline clinical characteristics
of the patients and control groups. Those patients who
had previous cancer, previous radiotherapy or chemother-
apy, and metastasized cancer from other or unknown ori-
gins were excluded. Control subjects were genetically
unrelated individuals and those with any personal or fam-
ily history of bladder cancer or other serious disease were
intentionally excluded. All subjects were Han population
living in Sichuan province of southwest China. This study
was approved by the ethics committee of West China
Second University Hospital and all subjects gave written
informed consent to participate.
DNA extraction and genotyping
Two single nucleotide polymorphisms (SNPs), rs153109
(also known as −964 A/G) and rs17855750 (also known as
2905 T/G), were genotyped in the present study. Genomic
DNA of each individual was extracted from 200 μl EDTA-
anticoagulated peripheral blood samples by a DNA isola-
tion kit from Bioteke (Peking, China) and the procedure
was performed according to the manufacturer’s instruc-
tions. Genotyping was performed using the polymerase
chain reaction (PCR) -restriction fragment length poly-
morphism (RFLP) method. Primers were established
with the PIRA PCR designer (http://primer1.soton.ac.uk/
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F: 5′-CTGATCCTGACCTCACTCAACGC-3′ and R: 5′-
CTGACTGGGACTGGGACTCAGC-3′ for rs153109.
The primers used for amplification of rs17855750 were
F: 5′-ATCTCGCCAGGAAGCTGCGC-3′ and R: 5′-
CTGTTAGTGGGGGCCAGAAGGGA-3′.
DNA fragments containing the polymorphisms were
amplified in a total volume of 25 μl, including 2.5 μl 10×
PCR buffer, 1.5 mmol/L MgCl2, 0.15 mmol/L dNTPs,
0.5 μmol/L each primer, 100 ng of genomic DNA and 1 U
of Taq DNA polymerase. The PCR conditions were 94 °C
for 4 min, followed by 32 cycles of 30 s at 94 °C, 30 s at
64 °C for rs153109 and 66 °C for rs17855750, and 30 s at
72 °C, with a final elongation at 72 °C for 10 min. PCR
products were digested overnight with specific restriction
enzyme and the digested products were separated by a
6 % polyacrylamide gel and stained with 1.5 g/L argent
nitrate: PaeR7I for rs153109, allele G is cuttable, yielding
two fragments of 45 bp and 179 bp, allele A is uncuttable
and the fragment is still 224 bp; and BstUI for
rs17855750, allele G is cuttable, yielding two fragments of
19 bp and 101 bp, allele T is uncuttable and the fragment
is still 120 bp. The genotypes were confirmed by the DNA
sequencing analysis. About 10 % of the samples were
randomly selected to perform the repeated assays and the
results were 100 % concordant.
Plasma IL-27 determination
For quantitative determination of IL-27, peripheral blood
from 124 patients (NMIBC/MIBC: 50/74; male/female:
96/28) and 151 controls (male/female: 115/36) was
collected into vaccutainer tubes containing EDTA-
anticoagulant. Samples were centrifuged at 3000 × g for
10 min and plasma was collected and stored at −80 °C
until use. Plasma levels of IL-27 were measured using
commercially available enzyme-linked immunosorbent
assay (ELISA) kits (USCNLIFE, Houston City, TX) accord-
ing to the manufacturer’s instructions. Developed color re-
action was measured as OD450 units on a multimode
microplate reader (TECAN Infinite M200, Switzerland).
The plasma concentration of IL-27 was determined using
standard curve constructed with the kit’s standards over
the range of 0–1000 pg/mL. The minimum detectable dose
of IL-27 was typically less than 5.9 pg/mL.
Statistical analyses
Data were analyzed using SPSS for Windows software
package version 13.0 (SPSS Inc., Chicago, IL, USA).
Genotype frequencies of these two SNPs were obtained
by directed counting and Hardy-Weinberg equilibrium
was evaluated by chi-square test. Odds ratio (OR) and
respective 95 % confidence intervals (CI) were reported
to evaluate the effects of any difference. Probability
values of 0.05 or less were regarded as statisticallysignificant, and all statistical tests were two sided. Geno-
typic association test in a case–control pattern assuming
codominant, dominant, recessive, or overdominant gen-
etic models was performed using SNPstats [35]. Allelic
association was performed by chi-square test. The
plasma IL-27 levels in patients with different IL-27 SNPs
genotype, and among NMIBC, MIBC and controls were
compared using the non-parametric Kruskal-Wallis test.
Tukey test was used for pairwise test. Mann Whitney
test was used to compare plasma levels of IL-27 of sub-
groups (age at first diagnosis, sex, smoking status and
tumor grade).
Kaplan-Meier plots and the log-rank test were used to
evaluate the association between genotypes of IL-27 SNPs,
plasma IL-27 levels with patients’ outcome from the date
of primary diagnosis until recurrence or death. Multivari-
ate survival analysis for the influence of IL-27 SNPs and
plasma IL-27 levels on patients’ outcome was carried out
by Cox regression analysis adjusted by the effect of age at
first diagnosis, sex and smoking status. Hazard ratio (HR)
and 95 % CI were calculated from the Cox regression
model including all factors for multiple analysis.
Results
IL-27 SNPs and susceptibility to bladder cancer
These two SNPs of IL-27, rs153109 and rs17855750, were
successfully genotyped in 332 patients with bladder cancer
and 499 control subjects. Three genotypes of each SNP
were identified and the genotypes were confirmed by the
DNA sequencing analysis. All observed genotype frequen-
cies in both patients and controls were in agreement with
that expected under the Hardy-Weinberg equilibrium.
Genotype distributions and allele frequencies of IL-27
SNPs in patients and controls are shown in Table 2. Sig-
nificant difference in genotype frequency distributions of
rs153109 was observed between bladder cancer patients
and controls (P = 0.029, OR = 1.37, 95 % CI = 1.03–1.82
for rs153109 in the dominant genetic model). For
rs17855750, no GG genotype was observed in 499
controls, while there were 4 patients carrying GG in 322
patients, suggesting that rs17855750 may be associated
with increased risk for bladder cancer in a recessive
genetic model (P = 0.006). There were no statistically sig-
nificant differences between patients and controls in terms
of the allele frequency distribution of rs153109 and
rs17855750.
IL-27 SNPs and patients’ characteristics
To further explore the effects of IL-27 SNPs on bladder
carcinogenesis, we conducted the stratified analyses.
Genotypic distributions of rs153109 and rs17855750 be-
tween NMIBC and MIBC patients are shown in Table 3.
No significant difference for the distribution of rs153109
between NMIBC and MIBC was observed. Compared to
Table 2 Distribution of SNPs in IL-27 among patients and controls and their association with bladder cancer risk
rs153109 rs17855750
Model Genotype Controls patients OR (95 % CI)a P valuea Genotype Controls patients OR (95 % CI)a P valuea
N = 499 (%) N = 332 (%) N = 499 (%) N = 332 (%)
Codominant AA 229 (45.9) 127 (38.2 %) 1.00 (reference) 0.075 TT 421 (84.4) 275 (82.8 %) 1.00 (reference) 0.022
AG 204 (40.9) 160 (48.2 %) 1.41 (1.05–1.92) TG 78 (15.6) 53 (16.0 %) 0.97 (0.66–1.42)
GG 66 (13.2) 45 (13.6 %) 1.23 (0.79–1.89) GG 0 4 (1.2 %) 0.00 (0.00-NA)
Dominant AA 229 (45.9) 127 (38.2 %) 1.00 (reference) 0.029 TT 421 (84.4) 275 (82.8 %) 1.00 (reference) 0.57
AG/GG 270 (54.1) 205 (61.8 %) 1.37 (1.03–1.82) TG/GG 78 (15.6) 57 (17.2 %) 0.90 (0.62–1.31)
Recessive AA/AG 433 (86.8) 287 (86.5 %) 1.00 (reference) 0.9 TT/TG 499 (100) 328 (98.8 %) 1.00 (reference) 0.006
GG 66 (13.2) 45 (13.6 %) 1.03 (0.68–1.54) GG 0 (0) 4 (1.2 %) 0.00 (0.00-NA)
Overdominant AA/GG 295 (59.1) 172 (51.8 %) 1.00 (reference) 0.037 TT/GG 421 (84.4) 279 (84.0 %) 1.00 (reference) 0.92
AG 204 (40.9) 160 (48.2 %) 1.35 (1.02–1.79) TG 78 (15.6) 53 (16.0 %) 0.98 (0.59–1.19)
Allele
A 662 (66.3) 414 (62.3) 1.19 (0.97–1.46) 0.096 T 920 (92.2) 603 (90.8) 1.20 (0.84–1.70) 0.317
G 336 (33.7) 250 (37.7) G 78 (7.8) 61 (9.2)
N corresponds to the number of individuals
aAdjusted by age, sex and smoking status
Boldfaced values indicate a significant difference at the 5 % level
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associated with an increased risk for MIBC (P = 0.042).Plasma IL-27 levels with susceptibility to bladder cancer
and IL-27 genotype
As shown in Fig. 1 and Table 4, by analyzing the plasma IL-
27 concentration of 124 bladder cancer patients and 151
controls, we found significant difference among NMIBC,
MIBC and controls (P < 0.0001). Results of Tukey's MultipleTable 3 Distribution of SNPs in IL-27 among NMIBC and MIBC patien
rs153109
Model Genotype NMIBC MIBC OR (95 % CI)a P v
N = 176 (%) N = 156 (%)
Codominant AA 66 (37.5 %) 61 (39.1 %) 1.00 (reference) 0
AG 87 (49.4 %) 73 (46.8 %) 1.04 (0.60–1.81)
GG 23 (13.1 %) 22 (14.1 %) 1.02 (0.46–2.27)
Dominant AA 66 (37.5 %) 61 (39.1 %) 1.00 (reference) 0
AG/GG 110 (62.5 %) 95 (60.9 %) 1.04 (0.62–1.75)
Recessive AA/AG 153 (86.9 %) 134 (85.9 %) 1.00 (reference) 0
GG 23 (13.1 %) 22 (14.1 %) 1.00 (0.48–2.09)
Overdominant AA/GG 89 (50.6 %) 83 (53.2 %) 1.00 (reference) 0
AG 87 (49.4 %) 73 (46.8 %) 1.04 (0.63–1.73)
Allele
A 219 (62.2) 195 (62.5) 0.99 (0.72–1.35) 0
G 133 (37.8) 117 (37.5)
N corresponds to the number of individuals
aAdjusted by age, sex and smoking status
Boldfaced values indicate a significant difference at the 5 % levelComparison Test showed IL-27 levels of NMIBC patients
(21.16 ± 2.91 pg/ml) were significantly decreased compared
with controls (38.21 ± 2.56 pg/ml). Although the IL-27
levels of MIBC patients (27.34 ± 5.72 pg/ml) were lower
than that of controls, the difference was not statistically sig-
nificant. There was no statistically significant difference for
plasma IL-27 levels between NMIBC and MIBC patients.
To study the association between genotype and pheno-
type, plasma IL-27 concentration in patients with respect
to IL-27 SNPs was investigated. As shown in Table 4, nots
rs17855750
aluea Genotype NMIBC MIBC OR (95 % CI)a P valuea
N = 176 (%) N = 156 (%)
.99 TT 149 (84.7 %) 126 (80.8 %) 1.00 (reference) 0.076
TG 26 (14.8 %) 27 (17.3 %) 0.53 (0.26–1.09)
GG 1 (0.6 %) 3 (1.9 %) 0.15 (0.01–1.84)
.88 TT 149 (84.7 %) 126 (80.8 %) 1.00 (reference) 0.042
TG/GG 27 (15.3 %) 30 (19.2 %) 2.04 (1.02–4.17)
.99 TT/TG 175 (99.4 %) 153 (98.1 %) 1.00 (reference) 0.14
GG 1 (0.6 %) 3 (1.9 %) 0.17 (0.01–2.07)
.88 TT/GG 150 (85.2 %) 129 (82.7 %) 1.00 (reference) 0.1
TG 26 (14.8 %) 27 (17.3 %) 0.55 (0.27–1.13)
.94 T 324 (92.0) 279 (89.4) 1.37 (0.81–2.32) 0.28
G 28 (8.0) 33 (10.6)
Fig. 1 Plasma levels of IL-27 in NMIBC, MIBC patients and controls
Table 4 Relationship between plasma levels of IL-27 and
patients’ characteristics
Variable analyzed IL-27 (pg/ml)
Total, N Mean SD SEM Median P
Case–control
Controls 151 38.21 28.76 2.56 37.80 < 0.0001
NMIBC 74 21.16 21.92 2.91 13.91
MIBC 50 27.34 32.87 5.72 18.41
Agea
≤65 88 26.49 32.23 4.8 16.33 0.94
>65 36 20.36 18.91 2.82 15.29
Sex
Male 96 24.13 27.14 3.22 16.33 0.43
Female 28 20.81 24.20 5.55 15.04
Smoking status
Smokers 73 22.86 25.80 3.42 16.33 0.55
Non-smokers 51 24.40 27.93 4.86 13.61
Tumor grade
Low grade 53 18.63 19.36 2.99 12.99 0.058
High grade 71 27.62 30.97 4.47 17.85
rs153109
AA 41 20.99 18.68 3.47 15.66 0.69
AG 61 26.07 31.37 4.44 15.69
GG 22 17.80 18.45 5.56 13.51
rs17855750
TT 101 25.11 28.21 3.35 15.66 0.055
TG 20 17.13 17.64 4.05 10.93
GG b 3 - - - -
N corresponds to the number of individuals
aThe threshold for age is based on median of bladder cancer patients
bPlasma IL-27 levels for all of these 3 samples were under the detection
threshold for the present ELISA kits and their value was conservative
determined as 5.9 pg/mL, which is the minimum detectable dose of IL-27
for the kits used in the present study
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genotype of rs153109 was observed. Interestingly, plasma
IL-27 levels for all of the 3 samples in rs17855750 GG
group were under the detection threshold for the present
ELISA kits and their value was conservative determined
as 5.9 pg/mL, which is the minimum detectable dose of
IL-27 for the kits used in the present study. Furthermore,
the plasma IL-27 levels in patients with homozygous TT
genotype were higher than that of heterozygous TG
genotype, suggesting that genotype of rs17855750 may be
associated with plasma IL-27 levels with an apparent
gene-dose effect, although not statistically significant with
a borderline P = 0.055.
No statistically significant association was found be-
tween plasma levels of IL-27 and patients’ characteristics
including age, sex, or smoking status (Table 4). While the
plasma IL-27 levels of patients with high grade (27.62 ±
4.47 pg/mL, n = 71) were higher than that of low grade
(18.63 ± 2.99 pg/mL, n = 53), although not statistically sig-
nificant (P = 0.058).
IL-27 SNPs, plasma IL-27 levels and outcome
There were 332 bladder cancer patients included in this
study. During the follow-up period, 51 patients (NMIBC:
13/176, MIBC: 38/156) had died and 281 patients alive
(NMIBC: 163/176, MIBC: 118/156), and 97 patients
(NMIBC: 50/176, MIBC: 47/156) had recurrence. The
age of the patients who were dead was 69.22 ± 9.89 years
compared with 62.80 ± 12.29 years in surviving patients
(P < 0.001), and 65.03 ± 11.35 years in recurrent patients
compared with 63.28 ± 12.47 years in non-recurrent
patients (P = 0.23) . As it’s well known that patients with
NMIBC have a better prognosis than patients with
MIBC, survival analysis were conducted in these different
populations independently.
IL-27 genotypes were subjected to multivariate survival
analysis adjusted by age at first diagnosis, sex and smoking
status (Table 5). No significant effect for rs153109 on over-
all survival or recurrence-free survival, and for rs17855750
on recurrence-free survival of both NMIBC and MIBC
patients was observed. Interestingly, rs17855750 may be
an independent protective factor for overall survival in
patients with MIBC. In the dominant genetic model, uni-
variate survival analysis indicated that MIBC patients with
allele G (TG/GG genotype) had a significantly decreased
risk for death than patients without allele G (TT genotype)
(HR = 0.21, 95 % CI = 0.05–0.90, P = 0.035) (Fig. 2). How-
ever, there was no association between rs17855750 and
overall survival of NMIBC patients (Fig. 3).
The association between plasma IL-27 levels and
survival was analyzed in 124 patients (NMIBC: 74,
MIBC: 50). During the follow-up period, 26 patients
(NMIBC: 8/74, MIBC: 18/50) had died and 37 patients
(NMIBC: 21/74, MIBC: 16/50) had recurrence. According
Table 5 Association between SNPs in IL-27 and patient’s survival
SNP/genotype NMIBC MIBC
Alive/dead, N HR (95 % CI)a P Recurrence/Non-recurrence HR (95 % CI)a P Alive/dead, N HR (95 % CI)a P Recurrence/Non-recurrence HR (95 % CI)a P
rs153109
AA 60/6 44/22 41/20 39/22
AG 82/5 64/23 58/15 55/18
GG 21/2 18/5 19/3 15/7
Dominant 1.58 (0.53–4.72) 0.41 1.49 (0.85–2.60) 0.17 1.76 (0.93–3.33) 0.09 1.25 (0.70–2.23) 0.46
Recessive 1.02 (0.22–4.69) 0.98 0.68 (0.27–1.74) 0.42 0.42 (0.13–1.38) 0.15 0.91 (0.40–2.07) 0.82
Overdominant
0.63 (0.21–1.94) 0.42 0.80 (0.46–1.41) 0.44 0.81 (0.42–1.56) 0.53 0.84 (0.46–1.53) 0.56
rs17855750
TT 137/12 105/44 90/36 87/39
TG 25/1 20/6 26/1 20/7
GG 1/0 1/0 2/1 2/1
Dominant 0.39 (0.05–3.10) 0.37 0.59 (0.24–1.42) 0.24 0.21 (0.05–0.90) 0.035 0.81 (0.37–1.77) 0.60
Recessive 0 (0-NA) 0.99 0 (0-NA) 0.97 1.09 (0.14–8.45) 0.94 1.40 (0.18–10.76) 0.75
Overdominant
0.42 (0.05–3.35) 0.41 0.61 (0.25–1.49 0.28 0.12 (0.02–0.88) 0.037 0.76 (0.33–1.74) 0.52
N corresponds to the number of individuals
aAdjusted by age, sex and smoking status











Fig. 2 Kaplan-Meier overall survival curve for MIBC patients based on rs17855750 genotypes
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ml for NMIBC and 18.41 pg/ml for MIBC, NMIBC and
MIBC patients were divided into two subgroups, and the
association of plasma IL-27 levels with survival was ana-
lyzed, respectively. We didn’t find any influence for the
plasma IL-27 levels on patients’ survival.
Discussion
In the present study, we have identified significant associa-
tions between IL-27 SNPs and susceptibility to bladderFig. 3 Kaplan-Meier overall survival curve for NMIBC patients based on rs17cancer, patients’ characteristics, and overall survival of
patients with MIBC. The association between different
genotype of rs17855750 and plasma IL-27 levels, and
significantly reduced plasma IL-27 levels compared to
controls has also been observed.
IL-27, composed of the EBI3 and IL-27p28 subunits, is
a member of the IL-12 family. EBI3 subunit was first
identified from a subtractive hybridization screen of
genes expressed in EBV transformed B cell lines in 1996
[36]. As a consequence of a computational approach to855750 genotypes
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IL-27p28 subunit was recognized as the partner for EBI3
[17]. IL-27 could synergize with IL-12 to promote prolif-
eration of naïve CD4+ T cells, but not memory CD4+ T
cells, and the production of IFN-γ from NK cells and
CD4+ T cells, suggesting that IL-27 function as a proin-
flammatory cytokine [17, 37]. Subsequent studies have
revealed the pleiotropic properties of IL-27 that can
limit or enhance ongoing immune responses depending
on context.
It has been 10 years since the first report on the anti-
tumor activity of IL-27 against a murine tumor model of
colon carcinoma C26, which suggested that IL-27 has
potent abilities to induce tumor-specific antitumor activity
and protective immunity and that the antitumor activity is
mediated mainly through CD8+ T cells, IFN-γ, and T-bet
but not through STAT4 [24]. In the same year, results
from TBJ murine neuroblastoma tumors also demon-
strated that IL-27 has a potent ability to induce tumor-
specific antitumor and protective immunity [38]. Since
then, the last decade has seen the description of the sig-
naling pathways engaged by IL-27, and an appreciation
has emerged that IL-27 can modulate the intensity and
duration of many classes of T cell responses [16]. IL-27
mediated antitumor mechanisms are complex, alone or in
combination with other cytokines, IL-27 boosts antitumor
immunity by contributing to the development of NK cells
and cytotoxic T cells (CTLs), and by exerting potent anti-
angiogenic and antimetastatic activities [21].
The associations between polymorphisms of IL-27 gene
and human diseases, including cancers, have been widely
studied [32, 33]. The SNP rs153109 has been reported to
be associated with susceptibility to asthma and inflamma-
tory bowel diseases in a Korean population, and with
chronic obstructive pulmonary disease in a Chinese popula-
tion, respectively [26–28]. Although no association between
IL-27 polymorphisms and immune thrombocytopenia,
esophageal cancer, glioma, type 1 diabetes, or nasopharyn-
geal was observed in previous reports, our recent study
suggested that IL-27 gene polymorphisms may play import-
ant roles in the susceptibility to epithelial ovarian cancer
[30, 31, 39–42]. The present study identified that IL-27
gene is associated with susceptibility to bladder cancer. Fur-
thermore, SNP rs17855750 turned out to be a protective
factor for overall survival in patients with MIBC. For the
first time, our data suggested that polymorphisms of IL-27
gene may play important roles in the initiation, promotion,
and progression of bladder cancer, especially in MIBC.
To date, few studies have reported the associations be-
tween serum/plasma IL-27 levels and human diseases.
Although there was no association between IL-27 gene
polymorphisms and glioma, the serum IL-27 levels were
decreased in glioma patients compared with controls.
Moreover, the authors reported that IL-12 gene 16974A/C polymorphism may regulate the expression of the
serum IL-12 and IL-27, but there were no significant
associations of the IL-27 gene polymorphisms with
serum levels of IL-27 [31]. It has also been reported that
serum/plasma levels of IL-27 decreased in epithelial
ovarian cancer, while increased in cutaneous T-cell
lymphoma, primary immune thrombocytopenia (ITP),
and gastroesophageal cancer [41, 43–45]. Interestingly,
although no significant association of rs153109 with
plasma levels of IL-27 was observed, our present data
indicated that genotype of rs17855750 may be associated
with plasma IL-27 levels with an apparent gene-dose
effect. Furthermore, plasma IL-27 levels for all of the 3
GG homozygous subjects which were identified only in
the case group were under the detection threshold. The
plasma levels of IL-27 among NMIBC, MIBC and
controls were significantly different, especially IL-27
levels of NMIBC were significantly decreased compared
with controls. While there was no difference between
NMIBC and MIBC, or between MIBC and controls. We
didn’t find any influence of plasma IL-27 levels on the
survival of patients, the present data suggested that
decreased plasma IL-27 levels may be associated with
increased susceptibility to bladder cancer.
A growing body of evidence has validated the protective
role of physiological levels of IL-27 against the develop-
ment and progression of carcinogen- and transgene-driven
neoplasms [22]. As it appears to have been associated with
reduced toxicity, IL-27 might be advantageous over other
cytokines in view of potential clinical applications [23]. No
study of IL-27 on bladder cancer has been reported, but
IL-27 has been reported to be effective in reducing tumor
growth and can promote enhanced accumulation of
effector cells in prostate tumors [46].
Taken together, the present study suggests that IL-27
gene polymorphisms are associated with susceptibility to
bladder cancer. The SNP rs17855750 may have a dual role
as both a predictor of bladder cancer and a prognostic
marker for patients’ survival. The decreased plasma levels
of IL-27 compared to controls observed in our present
study reinforces this predictive role as a marker of bladder
cancer.Conclusions
In conclusion, although our findings should be inter-
preted cautiously due to the limited number of patients
studied and sparse data, our present data lead us to
speculate that the assessment of IL-27 gene polymor-
phisms and plasma levels may be useful for predicting
susceptibility to bladder cancer and patients’ outcome.
Further studies with a larger number of patients and IL-
27 gene therapy in bladder cancer cells are warranted to
confirm these results.
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